Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/5/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Neil H. Bander MD

Wrong Dr. Neil H. Bander MD?

Professor - Tenure

Local Address: New York, New York, United States
Cornell University
159 Sapsucker Woods Road
Ithaca , New York 14850
United States

Company Description: Founded in 1865, Cornell is a leading private institution of higher learning located in Ithaca, New York. Approximately 20,000 students from 120 countries enroll in...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • M.D.
  • MD
52 Total References
Web References
Neil Bander, ...
www.adctherapeutics.com, 5 Nov 2014 [cached]
Neil Bander, M.D.
Chairman of Advisory Board
Neil H. Bander, MD is a physician-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan-Kettering Cancer Center. Since joining the faculty of Cornell University Medical College (now Weill-Cornell Medical College) and New York-Presbyterian Hospital, he has directed both a laboratory effort and translational clinical research program to discover and clinically develop monoclonal antibodies for targeted cancer imaging and therapy.
Dr. Bander's team has the world's largest experience in antibody discovery and clinical development in urological cancers. His group developed the first series of monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could target and bind viable prostate cancer cells. In part as a result of Dr. Bander's efforts, PSMA has become recognized as the most prostate-cancer specific cell surface antigen known. His team and collaborators have developed PET imaging agents as well as radiolabeled- and drug-conjugated antibodies that have entered phase 1 and 2 clinical trials now extending to a dozen leading academic medical centers in the US.
The lead radiolabeled antibody is slated for international phase 3 trials in the coming months. Dr. Bander has long-standing interests and activities in the antibody-drug conjugate field. Via joint efforts with multiple industry collaborators, Dr. Bander has direct experience with virtually every major drug-linker platform available. He lectures and writes frequently on the topic.
In addition to collaborates with multiple academic groups, Dr. Bander also serves as a consultant and Advisory Board member to several bio-pharmaceutical companies. He is a Joint Steering Committee member of the Pfizer-Weill/Cornell Center for Technological Innovation. Antibodies developed in his lab have been licensed to multiple bio-pharma companies for further development and commercialization.
Dr. Bander has authored approximately 175 peer-reviewed publications, and he is an inventor on approximately 100 US and foreign issued and pending patents. He has received several honors including the FC Valentine Fellowship from the NY Academy of Med, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clarke Medal for Surgical Innovation from the Royal College of Surgeons (London).
...
Neil Bander, M.D. Chairman of Advisory Board
Dr. Neil Bander, ...
www.adctherapeutics.com, 25 Feb 2014 [cached]
Dr. Neil Bander, Chairman
Dr. Neil H. Bander, MD is a physician-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan-Kettering Cancer Center. Since joining the faculty of Cornell University Medical College (now Weill-Cornell Medical College) and New York-Presbyterian Hospital, he has directed both a laboratory effort and translational clinical research program to discover and clinically develop monoclonal antibodies for targeted cancer imaging and therapy.
Dr. Bander's team has the world's largest experience in antibody discovery and clinical development in urological cancers. His group developed the first series of monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could target and bind viable prostate cancer cells. In part as a result of Dr. Bander's efforts, PSMA has become recognized as the most prostate-cancer specific cell surface antigen known. His team and collaborators have developed PET imaging agents as well as radiolabeled- and drug-conjugated antibodies that have entered phase 1 and 2 clinical trials now extending to a dozen leading academic medical centers in the
US. The lead radiolabeled antibody is slated for international phase 3 trials in the coming months. Dr. Bander has long-standing interests and activities in the antibody-drug conjugate field. Via joint efforts with multiple industry collaborators, Dr. Bander has direct experience with virtually every major drug-linker platform available. He lectures and writes frequently on the topic.
In addition to collaborates with multiple academic groups, Dr. Bander also serves as a consultant and Advisory Board member to several bio-pharmaceutical companies. He is a Joint Steering Committee member of the Pfizer-Weill/Cornell Center for Technological Innovation. Antibodies developed in his lab have been licensed to multiple bio-pharma companies for further development and commercialization.
Dr. Bander has authored approximately 175 peer-reviewed publications, and he is an inventor on approximately 100 US and foreign issued and pending patents. He has received several honors including the FC Valentine Fellowship from the NY Academy of Med, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clarke Medal for Surgical Innovation from the Royal College of Surgeons (London).
UsTOO New York About Page
www.ustoonewyork.org, 31 May 2014 [cached]
NEIL BANDER, MD Chaus Professor of Urologic Oncology
The PSMA-specific J591 antibody in ...
www.adctherapeutics.com, 19 May 2014 [cached]
The PSMA-specific J591 antibody in ADCT-401 was developed by Dr. Neil H. Bander, the Bernard & Josephine Chaus Professor of Urologic Oncology and Director of Urological Oncology Research at the Weill-Cornell Medical College, New York. Dr. Bander is also Chairman of ADCT's Scientific Advisory Board. PSMA is a cell-surface antigen expressed by virtually all prostate cancer cells, including metastases, and also in the blood vessels that feed many other tumor types, but is rarely expressed in normal cells.
"PSMA is an ideal target for an ADC therapeutic strategy because it is unparalleled in its prostate cancer specificity, its high density of expression and its very efficient internalization," said Dr. Neil Bander. "If the preclinical efficacy and safety studies translate into the clinic, ADCT-401 has the potential to be a breakthrough therapy in the treatment of advanced, refractory prostate cancers. I am delighted that the ADCT and MedImmune teams have combined their efforts to advance it into patients as quickly as possible," he added.
Neil Bander, M.D., ...
www.PEGSummit.com [cached]
Neil Bander, M.D., Professor, Weill Cornell Medical College
Neil H. Bander, M.D., is a physician-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan-Kettering Cancer Center. Since joining the faculty of Cornell University Medical College (now Weill-Cornell Medical College) and New York-Presbyterian Hospital, he has directed both a laboratory effort and translational clinical research program to discover and clinically develop monoclonal antibodies for targeted cancer imaging and therapy. Dr. Bander's team developed the first series of monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could target and bind viable prostate cancer cells. In addition to collaborations with multiple academic groups, Dr. Bander also serves as a consultant and Advisory Board member to several bio-pharmaceutical companies including ADC Therapeutics sarl, Bind Therapeutics, BZL Biologics, Inc., and MedImmune. He is a Joint Steering Committee member of the Pfizer-Weill/Cornell Center for Technological Innovation. Antibodies developed in his lab have been licensed to multiple bio-pharma companies for further development and commercialization. Dr. Bander has authored approximately 175 peer-reviewed publications, and he is an inventor on approximately 100 US and foreign issued and pending patents. He has received several honors including the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clarke Medal for Surgical Innovation from the Royal College of Surgeons (London).
Other People with the name "Bander":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.